JP2017517520A5 - - Google Patents

Download PDF

Info

Publication number
JP2017517520A5
JP2017517520A5 JP2016569847A JP2016569847A JP2017517520A5 JP 2017517520 A5 JP2017517520 A5 JP 2017517520A5 JP 2016569847 A JP2016569847 A JP 2016569847A JP 2016569847 A JP2016569847 A JP 2016569847A JP 2017517520 A5 JP2017517520 A5 JP 2017517520A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
composition according
patient
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016569847A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017517520A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/032351 external-priority patent/WO2015183776A1/en
Publication of JP2017517520A publication Critical patent/JP2017517520A/ja
Publication of JP2017517520A5 publication Critical patent/JP2017517520A5/ja
Pending legal-status Critical Current

Links

JP2016569847A 2014-05-29 2015-05-26 Ｗｅｅ１阻害剤を用いた癌を処置する方法 Pending JP2017517520A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004298P 2014-05-29 2014-05-29
US62/004,298 2014-05-29
PCT/US2015/032351 WO2015183776A1 (en) 2014-05-29 2015-05-26 Methods for treating cancer with a wee1 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019232432A Division JP2020073520A (ja) 2014-05-29 2019-12-24 Ｗｅｅ１阻害剤を用いた癌を処置する方法

Publications (2)

Publication Number Publication Date
JP2017517520A JP2017517520A (ja) 2017-06-29
JP2017517520A5 true JP2017517520A5 (enExample) 2018-06-28

Family

ID=54699632

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016569847A Pending JP2017517520A (ja) 2014-05-29 2015-05-26 Ｗｅｅ１阻害剤を用いた癌を処置する方法
JP2019232432A Pending JP2020073520A (ja) 2014-05-29 2019-12-24 Ｗｅｅ１阻害剤を用いた癌を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019232432A Pending JP2020073520A (ja) 2014-05-29 2019-12-24 Ｗｅｅ１阻害剤を用いた癌を処置する方法

Country Status (4)

Country Link
US (3) US20170095479A1 (enExample)
EP (1) EP3148544A4 (enExample)
JP (2) JP2017517520A (enExample)
WO (1) WO2015183776A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017517520A (ja) * 2014-05-29 2017-06-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｗｅｅ１阻害剤を用いた癌を処置する方法
WO2019134070A1 (en) * 2018-01-02 2019-07-11 Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine Panda as novel therapeutic
EA202191730A1 (ru) 2018-12-20 2021-08-24 Эмджен Инк. Ингибиторы kif18a
US20230008362A1 (en) * 2019-12-20 2023-01-12 Recurium Ip Holdings, Llc Combinations
CN115667551A (zh) * 2020-04-14 2023-01-31 美国安进公司 用于治疗赘生性疾病的kif18a抑制剂
CA3180664A1 (en) * 2020-06-17 2021-12-23 Yuli Xie Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor
KR20230028371A (ko) * 2020-06-24 2023-02-28 피엠브이 파마슈티컬스 인코포레이티드 돌연변이 p53 재활성화 화합물에 대한 동반 진단 도구
EP4392407A1 (en) 2021-08-26 2024-07-03 Volastra Therapeutics, Inc. Spiro indoline inhibitors of kif18a
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101784551A (zh) * 2007-06-15 2010-07-21 万有制药株式会社 二环苯胺衍生物
US20120157342A1 (en) * 2009-09-02 2012-06-21 Shinji Mizuarai Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
CA2817968C (en) * 2010-11-16 2019-03-12 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
US9506926B2 (en) * 2011-02-18 2016-11-29 The Regents Of The University Of California Molecular predictors of therapeutic response to specific anti-cancer agents
US9345705B2 (en) * 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
JP2017517520A (ja) * 2014-05-29 2017-06-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｗｅｅ１阻害剤を用いた癌を処置する方法

Similar Documents

Publication Publication Date Title
JP2017517520A5 (enExample)
JP2016525097A5 (enExample)
PE20170312A1 (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso
JP2015533176A5 (enExample)
JP2016533366A5 (enExample)
MX2021001583A (es) Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso.
JP2018507249A5 (enExample)
NZ602385A (en) Methods of treating cancer
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
MX2018005071A (es) Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp.
JO3556B1 (ar) علاجات مدمجة لمعالجة السرطان
MX2015011752A (es) Metodos para tratar cancer de pulmon.
PH12015502046B1 (en) Pyridinyl and fused pyridinyl triazolone derivatives
JP2015536950A5 (enExample)
PH12016502354A1 (en) Pharmaceutical composition
MX2017015936A (es) Nueva composicion farmaceutica que comprende agentes tensioactivos no ionicos.
MX2018004328A (es) Composiciones farmaceuticas estabilizantes de camptotecina.
MX2020004476A (es) Compuestos piridinicos de pladienolida y metodos de uso.
WO2014180889A8 (en) Methods and compositions for the treatment of cancer
WO2013112950A3 (en) Certain chemical entities, compositions, and methods
GB2538683A8 (en) Irinotecan hydrochloride composite phospholipid composition preparation method and use thereof
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
JP2015502926A5 (enExample)
WO2016127168A3 (en) Mebendazole polymorph for treatment and prevention of tumors